COMBINATION THERAPY FOR CANCER

The present invention relates to the field of medicine. More particularly, the present disclosure relates to combinations of an antibody that binds colony-stimulating factor 1 receptor (CSF-IR) and an antibody that binds human programmed cell death I ligand 1 (PD-L1) and to methods of using the comb...

Full description

Saved in:
Bibliographic Details
Main Author SCHAER, David Arlen
Format Patent
LanguageEnglish
French
German
Published 03.10.2018
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the field of medicine. More particularly, the present disclosure relates to combinations of an antibody that binds colony-stimulating factor 1 receptor (CSF-IR) and an antibody that binds human programmed cell death I ligand 1 (PD-L1) and to methods of using the combination to treat cancer, and in particular solid tumors with macrophage infiltration.
Bibliography:Application Number: EP20160809588